AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05692791 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Two-point Discrimination Test
Description: Two-point discrimination (2PD) is the ability to discern that two nearby objects touching the skin are truly two distinct points, not one. It is often tested with two sharp points during a neurological examination and is assumed to reflect how finely innervated an area of skin is.
Study NCT05692791 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Semmes-Weinstein monofilament test
Description: Semmes-Weinstein monofilament test is used to assess light touch sensations.
Study NCT05459116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of nasogastric balloon
Description: A nasogastric balloon catheter will be inserted after inclusion. This will be a NutriVent (Sidam S.R.L., Mirandola, Italy) for patients >40kg, and a SmartCath Esophageal pressure catheter (Vyaire/Carefusion) for patients \<40kg. This placement is similar to a standard nasogastric tube placement, which is a common procedure in an ICU. Potential minor side effects include a nosebleed, sore throat and erosion of the nose where the tube is anchored. All patients will receive this intervention. When the esophageal catheter becomes displaced or is accidentally removed during the study period, it will be replaced.
Study NCT06241157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric Quiz Game
Description: Investigator will start interacting with children upon their arrival and during their presence in the waiting room before entering the operating room. This will help to obtain better cooperation (frankl scale) and anxiety reductions (FIS and VPT) at different stages of the dental examination (e.g., entering the clinic, sitting on the dental chair, opening mouth, examination with mirror, probe, use of low-high-speed handpieces, ITR restoration). Pediatric Quiz is actually an ice-breaking quiz game developed for children, with the promise of a surprise gift at the end. It can be defined as asking children basic questions on colors, animals, fruits and/or cities depending on the age of the child among which the child would choose him/herself and answer the question easily.
Study NCT05939102 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: v-prep combined with RMGIC for bracket bonding
Description: prepare the tooth surface with the V-prep, then bond a bracket with the RMGIC
Study NCT05939102 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional bracket bonding technique
Description: prepare the tooth with acid-etch, then bond a bracket using resin composite
Study NCT05123885 — intervention group
Intervention type: OTHER
Intervention: Study on Data
Description: Study on Data
Study NCT05490095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SVG101 (T)
Description: 5mg of SVG101
Study NCT05490095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afinitor (R)
Description: 5mg of Afinitor
Study NCT05216146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength and Conditioning
Description: A specially designed strength and conditioning program will be delivered for a period of 6 months from the experienced strength and conditioning coaches. The program will consist of the basic aerobic and anaerobic exercises that could be practiced without additional equipment and with own body weight.
Study NCT05216146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength and Conditioning
Description: A specially designed strength and conditioning program will be delivered for a period of 6 months from the experienced strength and conditioning coaches. The program will consist of the basic aerobic and anaerobic exercises that could be practiced without additional equipment and with own body weight.
Study NCT05686252 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Held Position
Description: Change in angle of held position during kangaroo mother care to alternative angle
Study NCT05516407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEN164
Description: Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
Study NCT05814614 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pelvic physical therapy
Description: Pelvic floor muscle exercises, biofeedback, bladder training
Study NCT05814614 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: pelvic physical therapy
Description: Pelvic floor muscle exercises, biofeedback, bladder training
Study NCT04983238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYON5667 & SYD985
Description: Ocular administration: BYON5667, Intravenous administration: SYD985
Study NCT04983238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo & SYD985
Description: Ocular administration: Placebo, Intravenous administration: SYD985
Study NCT04876664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: measuring blood pressure with noninvasive blood pressure device
Description: To measure blood pressure in different circumstances with noninvasive blood pressure device
Study NCT06096233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bouts of Exercise
Description: The participants will run on the treadmill for 10 minutes (short) or 30 minutes (prolonged).
Study NCT04740879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be Mindful
Description: The online 4-week Be Mindful intervention was designed to follow the same outline as typical in-person 8-week MBCT courses. Week 1 and Week 2 introduce the topic of mindfulness and encourage its daily use, whereas Week 3 and Week 4 teach the individual to decenter from thoughts and utilize mindfulness when coping with stressors. Each week focuses on a separate mindfulness topic, which is initially presented to the individual in a short (under 5 minute) video containing didactic information and an overview of the experiential activities that will be introduced in subsequent videos. The intervention is provided entirely through audio, video, and text provided on the Be Mindful website (BeMindfulOnline.com).
Study NCT04740879 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Be Mindful
Description: The online 4-week Be Mindful intervention was designed to follow the same outline as typical in-person 8-week MBCT courses. Week 1 and Week 2 introduce the topic of mindfulness and encourage its daily use, whereas Week 3 and Week 4 teach the individual to decenter from thoughts and utilize mindfulness when coping with stressors. Each week focuses on a separate mindfulness topic, which is initially presented to the individual in a short (under 5 minute) video containing didactic information and an overview of the experiential activities that will be introduced in subsequent videos. The intervention is provided entirely through audio, video, and text provided on the Be Mindful website (BeMindfulOnline.com).
Study NCT05205720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Celiac plexus block
Description: The surgeon is instructed to perform a single celiac plexus block under direct vision. 10ml 0.5% ropivacaine is injected into the nerve in both sides.
Study NCT05005013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through sponge electrodes placed on the scalp.
Study NCT05005013 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham - Transcranial Direct Current Stimulation (tDCS)
Description: The tDCS device is programmed to mimic active tDCS.
Study NCT05005013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Participants will follow an audio track for guided mindfulness during the stimulation.
Study NCT05005013 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mindfulness
Description: Participants will follow an audio track for guided mindfulness during the stimulation.
Study NCT05951088 — intervention group
Intervention type: PROCEDURE
Intervention: Cardio2U follow-up
Description: During the follow-up period, participants will have access to the application and will be able to explore the different modules. At fixed time points, the application will allow them to fill in questionnaires about the application's usability and patient satisfaction. App user data will track how long and how often patients visit the application and which aspects are mostly used. In addition, at different time points during the study, patients will be asked to complete clinical questionnaires regarding e.g. patients' knowledge and self-care abilities. The results of these questionnaires can be used in a more clinical way as they will be accessible to doctors and nurses in the healthcare provider dashboard and can support targeted patient follow-up and guidance
Study NCT06315660 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Miljeu Therapy
Description: TAU is an integrated voluntary inpatient treatment based on the principles of CBT, lasting between 12-20 weeks. This treatment includes exercise, close medical monitoring, group-based CBT for SUD, planning with social services, and is called Cognitive Milieu Therapy.
Study NCT06315660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Miljeu Therapy
Description: TAU is an integrated voluntary inpatient treatment based on the principles of CBT, lasting between 12-20 weeks. This treatment includes exercise, close medical monitoring, group-based CBT for SUD, planning with social services, and is called Cognitive Milieu Therapy.
Study NCT06315660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality based CBT for Anxiety
Description: The experimental intervention is a manualized add-on to TAU and comprises eight sessions of 60 minutes over a period of four weeks. Of these eight sessions, six will include 30 minutes of VR-based behavioral experiments targeting agoraphobic and social fear.
Study NCT05205720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Mixed solution for nerve block, made of 0.75% ropivacaine (Naropin, Astrazeneca AB) diluted in different proportions.
Study NCT06514729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adopting different ventilation modes during the operation
Description: The ventilation side adopts different ventilation modes combined with continuous positive pressure ventilation on the surgical side.
Study NCT04756674 — intervention group
Intervention type: OTHER
Intervention: No intervetion will be used
Description: No intervention will be used
Study NCT06106022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Administered orally
Study NCT05828446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: To compare the diagnostic performance of US+/- Constrast-enhanced US and AMRI for HCC detection in an at-risk population
Study NCT05941884 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry staining,
Description: Tissue samples:~* Histopathological examination: Hematoxylin and Eosin slides will be prepared and examined.~  * The only dependable criterion for the diagnosis of bilharzial infestation is the microscopic detection of Bilharzia ova in pathological sections.~ * Pathology (cystitis- cancer and its grade staging will be reported in accordance with the 2022 World Health Organization Classification of Tumors of the Urinary System (17).~* To quantify levels of Nuclear factor kappa B and protein kinase c α:~  * Immunohistochemistry according to the manufacturer's instructions.
Study NCT05941884 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: microscopic examination of urine
Description: Urine samples:~* Mic roscopic examination (detection of S. haematobium egg - egg counting)~* Detection of HSP 70 Measurements: indirect ELISA will be used to quantify HSP concentrations in urine.
Study NCT06295159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.
Study NCT05353530 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells
Description: Single dose of 8R-70CAR T cells administered IV
Study NCT06669572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.~Pembrolizumab will be given for a maximum of 2 years (total 35 cycles) with dosing every 3 weeks.
Study NCT06669572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be taken once daily, with or without food, at the same time each day.
Study NCT06295159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Relatlimab
Description: Opdualag (Nivolumab and Relatlimab-rmbw) is a combination formulation composed of nivolumab, a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), and relatlimab-rmbw, a human IgG4 monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3). Nivolumab binds to and blocks the activation of PD-1 by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This prevents PD-1-mediated signaling and PD-1-mediated inhibition of the immune response. Relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs) and prevents LAG-3 binding to major histocompatibility complex (MHC) class II. This prevents LAG-3-mediated signaling and LAG-3-mediated inhibition of the immune response.
Study NCT05290519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plant and animal protein
Description: plant protein: 2 bottle of black soy milk (400 mL/bottle) for 4 weeks animal protein: pork dished for 4 weeks
Study NCT06295159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a type of monoclonal antibody and a type of immune checkpoint inhibitor that may block CTLA-4 and help the immune system kill cancer cells. Ipilimumab binds to the protein CTLA-4 to help immune cells kill cancer cells better and is used to treat many different types of cancer. These include cancers that have certain mutations (changes) in genes involved in DNA repair.
Study NCT04946253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DOCC: Evidence-based treatment for disruptive behavior and ADHD
Description: Practices will learn and then deliver DOCC in treatment sessions with caregivers and/or children. The content covers key topics related to the treatment of behavior problems (e.g., self-management, positive parenting) and ADHD (e.g., psychoeducation, medication).
Study NCT04946253 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DOCC: Evidence-based treatment for disruptive behavior and ADHD
Description: Practices will learn and then deliver DOCC in treatment sessions with caregivers and/or children. The content covers key topics related to the treatment of behavior problems (e.g., self-management, positive parenting) and ADHD (e.g., psychoeducation, medication).
Study NCT04946253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEAM: Implementation support strategies at the care team level following standard implementation of DOCC
Description: Practices will learn and then deliver DOCC in treatment sessions with caregivers and/or children. Coaching and consultation will be provided to the provider care team to support the use of collaborative care for behavior problems and ADHD. The TEAM intervention includes regular virtual meetings or calls with the providers (about once/month, on average) that cover core chronic care model functions, including registry use, case-finding, collaborative care team roles, and workflows outlining how DOCC is delivered in the practice.
Study NCT04946253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation support strategies at the leadership level following standard implementation of DOCC
Description: Practices will learn and then deliver DOCC in treatment sessions with caregivers and/or children. Practice facilitation will be provided to practice leaders to help them support the care team's use of collaborative care for behavior problems and ADHD. The LEAD intervention includes regular virtual meetings or calls with practice leaders (about once/month, on average) that cover the assessment of practice capacity/barriers, ways to overcome organizational barriers and support staff use of DOCC, promoting innovation, and leveraging practice resources to support DOCC delivery and maintenance in the practice.
Study NCT05871892 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 18F-FDGal PET/CT or PET/MRI
Description: All patients suspected of or diagnosed with HCC will be offered an initial 18F-FDGal PET/CT or PET/MRI scan. Moreover, patients who undergo loco-regional treatment (resection, ablation (radiation or microwave), chemo- or radio-embolization) are re-examined with 18F-FDGal. The scans will be performed 1-2 months and 3-5 months after the loco-regional treatment. The images will be analyzed by an experienced PET specialist and the CT or MR images by an experienced radiologist for focal lesions and compared to other imaging modalities. The investigators expect approximately 25 patients per year during a 5-year period and as such aim at a total of 125 patients
Study NCT05072886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT193
Description: Topical applied to affected areas daily
Study NCT05072886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AT193
Description: Topical applied to affected areas daily
Study NCT06744673 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study NCT06745076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06745076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05393908 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block Group
Description: Participants will receive a surgeon administered TAP block.
Study NCT04927988 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ringer's Lactated
Description: Using of Ringer's Lactated In Autologous Blood Cell Transfusion
Study NCT06331572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 17-HAMD
Description: Patients were interviewed in a semi-structured manner and assessed using the 17-item Hamilton Depression Scale and the Hamilton Anxiety Scale
Study NCT05575245 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting Stent
Description: Drug-eluting Stent angioplasty
Study NCT05575245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer Laser Ablation Combined Drug-coated Balloon
Description: Excimer Laser Ablation Combined Drug-coated Balloon angioplasty
Study NCT06745076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV
Study NCT05782244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate low dose
Description: Sildenafil citrate 20 mg, oral, TID
Study NCT05782244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral, TID
Study NCT05782244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil medium dose
Description: Sildenafil 40 mg, oral, TID
Study NCT05782244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil high dose
Description: Sildenafil 80 mg, oral, TID
Study NCT04669093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo cream- promotion suggestion
Description: Over-the-counter hand cream will be applied to participants' skin, but they will be told that they are given a highly efficient topical analgesic cream. The suggestion will be based on a promotion approach (promoting good feelings).
Study NCT04669093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo cream- prevention suggestion
Description: Over-the-counter hand cream will be applied to participants' skin, but they will be told that they are given a highly efficient topical analgesic cream. The suggestion will be based on a prevention approach (preventing pain).
Study NCT04669093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control cream
Description: In a control condition, with the same cream as in the placebo interventions, participants will be instructed that the cream is a control cream with no effects.
Study NCT06432452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endothelin Receptor Antagonist
Description: Oral capsules twice daily
Study NCT06432452 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Oral capsules twice daily